This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Evoke Pharma Stock (NASDAQ:EVOK) Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$10.98▼$11.0050-Day Range$10.67▼$11.0052-Week Range$2.28▼$11.00Volume47,100 shsAverage Volume983,927 shsMarket Capitalization$18.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Evoke Pharma, Inc. is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function. In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology. The company’s research efforts aim to extend the therapeutic potential of ghrelin receptor modulation into related indications, including postoperative ileus and chronic constipation. Evoke collaborates with academic and industry partners to optimize its pipeline and expand clinical development into new patient populations. Founded in 2006 and headquartered in San Diego, California, Evoke Pharma completed its initial public offering on the Nasdaq under the ticker EVOK. The company serves patients across the United States and is exploring opportunities to establish international partnerships for broader market access. Evoke’s leadership team combines decades of experience in gastroenterology drug development, regulatory affairs and commercial strategy to advance its mission of improving quality of life for individuals with debilitating GI disorders.AI Generated. May Contain Errors. Read More Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVOK Stock News HeadlinesEvoke Agrees to $326 Million Takeover Bid From Bally's IntralotJune 5, 2026 | wsj.comWilliam Hill UK owner Evoke agrees $326 million takeover by Bally's IntralotJune 5, 2026 | reuters.comNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.August 8 at 1:00 AM | Brownstone Research (Ad)William Hill UK owner Evoke confirms $304 million takeover bid from Bally's IntralotApril 20, 2026 | reuters.comQOL Medical, LLC: Evoke Pharma and QOL Medical Announce Expiration of Tender OfferDecember 17, 2025 | finanznachrichten.deEvoke Pharma and QOL Medical Announce Expiration of Tender OfferDecember 17, 2025 | prnewswire.comEvoke assesses Italian unit sale amid tax concerns ahead of budget, Sky News reportsNovember 25, 2025 | reuters.comGLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide missNovember 24, 2025 | msn.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) posted its earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.32. The specialty pharmaceutical company had revenue of $3.75 million for the quarter, compared to analyst estimates of $3.80 million. Evoke Pharma had a negative trailing twelve-month return on equity of 101.40% and a negative net margin of 36.23%. When did Evoke Pharma's stock split? Evoke Pharma's stock reverse split on Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Evoke Pharma IPO? Evoke Pharma (EVOK) raised $27 million in an initial public offering (IPO) on Wednesday, September 25th 2013. The company issued 2,100,000 shares at $12.00-$14.00 per share. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/14/2025Today8/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 EVOK's financial health is in the Green zone, according to TradeSmith. EVOK has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EVOK CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year Founded2007Profitability EPS (Trailing Twelve Months)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.35 million Net Margins-36.23% Pretax Margin-36.23% Return on Equity-101.40% Return on Assets-31.86% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.22 Sales & Book Value Annual Sales$10.25 million Price / Sales1.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book2.32Miscellaneous Outstanding Shares1,720,000Free Float1,683,000Market Cap$18.92 million OptionableNot Optionable Beta-0.15 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:EVOK) was last updated on 8/8/2026 by MarketBeat.com Staff. From Our PartnersSpaceX Earnings Crash: The End of the AI Bubble?Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. ...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredWhy Trump really wants GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then,...Porter & Company | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
